| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D243-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-536
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-662
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-655
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-683
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-568
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 |
| filingDate |
2006-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2009-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e8a26bd745c953ff78961098d77d3223
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6b6c17eb6b0593d8d44d2755c842ce0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2ef289b7f1350ff60b0dd862a3f33bc |
| publicationDate |
2009-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7494984-B2 |
| titleOfInvention |
Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors |
| abstract |
The invention encompasses a series of bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8129398-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010087419-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8143244-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8383639-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009253677-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8513234-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010216774-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017044314-A1 |
| priorityDate |
2005-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |